Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0006142 (
breast cancer
)
160,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin-like growth factor (IGF) signaling is a key regulator of breast development and
breast cancer
. We have analyzed the expression of the IGF signaling cascade in 17 human
breast cancer
and 4 mammary epithelial cell lines. Five cell lines expressed high levels of IGF1 receptor, insulin (INS)/IGF receptor substrate 1, IGF-binding proteins 2 and 4, as well as the estrogen receptor (ESR), indicating a co-activation of IGF and ESR signaling. Next, we stably overexpressed IGF1 and IGF2 in MCF7
breast cancer
cells, which did not affect their epithelial characteristics and the expression and localization of the epithelial marker genes E-cadherin and beta-catenin. Conversely, IGF1 and IGF2 overexpression potently increased cellular proliferation rates and the efficiency of tumor formation in mouse xenograft experiments, whereas the resistance to chemotherapeutic drugs such as taxol was unaltered. Expression profiling of overexpressing cells with whole-genome oligonucleotide microarrays revealed that 21 genes were upregulated >2-fold by both IGF1 and IGF2, 9 by IGF1, and 9 by IGF2. Half of the genes found to be upregulated are involved in transport and biosynthesis of amino acids, including several amino acid transport proteins, argininosuccinate and asparagine synthetases, and
methionyl-tRNA synthetase
. Upregulation of these genes constitutes a novel mechanism apparently contributing to the stimulatory effects of IGF signaling on the global protein synthesis rate. We conclude that the induction of cell proliferation and tumor formation by long-term IGF stimulation may primarily be due to anabolic effects, in particular increased amino acid production and uptake.
...
PMID:Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. 1677 35
Although abnormal increases in the level or activity of cyclin-dependent kinase 4 (CDK4) occur frequently in cancer, the underlying mechanism is not fully understood. Here, we show that
methionyl-tRNA synthetase
(
MRS
) specifically stabilizes CDK4 by enhancing the formation of the complex between CDK4 and a chaperone protein. Knockdown of
MRS
reduced the CDK4 level, resulting in G0/G1 cell cycle arrest. The effects of
MRS
on CDK4 stability were more prominent in the tumor suppressor p16
INK4a
-negative cancer cells because of the competitive relationship of the two proteins for binding to CDK4. Suppression of
MRS
reduced cell transformation and the tumorigenic ability of a p16
INK4a
-negative
breast cancer
cell line
in vivo
. Further, the
MRS
levels showed a positive correlation with those of CDK4 and the downstream signals at high frequency in p16
INK4a
-negative human
breast cancer
tissues. This work revealed an unexpected functional connection between the two enzymes involving protein synthesis and the cell cycle.
...
PMID:Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16
INK4a
-Negative Cancer. 3221 2